Sellas Life Sciences Shares Surge on Encouraging Clinical Trial Data

Shares of Sellas Life Sciences are posting significant gains in today’s trading session. This upward momentum follows the release of compelling clinical trial results for the company’s drug candidate, SLS009, presented at the annual meeting of the American Society of Hematology (ASH). The data, drawn from a Phase 2 study targeting an aggressive form of acute myeloid leukemia (AML), has resonated strongly with the investment community.

The investigational therapy, SLS009, is a highly selective CDK9 inhibitor evaluated in combination with standard treatments. Within the trial cohort of patients with relapsed or refractory AML, the regimen demonstrated a robust overall response rate of 46%. Notably, nearly one-third of evaluable patients Read more...